Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

378
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
378
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

511
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
511
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

314
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314
Hormonal Regulation01:33

Hormonal Regulation

32.9K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.9K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-HMGCR Myopathy During NSTEMI Evaluation: The Statin Paradox and Troponin Trap.

JACC. Case reports·2026
Same author

Major adverse cardiovascular events after liver transplantation: a population cohort analysis of English transplant centres.

EClinicalMedicine·2026
Same author

Evolving Trends in Organ Donation and Transplantation Rates Across Muslim Majority Countries.

Transplant international : official journal of the European Society for Organ Transplantation·2025
Same author

Common Themes and Uncertainties in Management of Secondary Polycythaemia: An International Clinician Survey of Practice.

EJHaem·2025
Same author

Thrombotic microangiopathy multidisciplinary assessment team: demographics, final diagnosis, treatment, and outcomes.

BMC nephrology·2025
Same author

Prevalence of Multidrug-Resistant Tuberculosis and Its Association With Previous Treatment History in Adults.

Cureus·2025

Related Experiment Video

Updated: Jun 1, 2025

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

9.9K

Exploring Neurohormonal Modulation by Acetazolamide in Heart Failure.

Midhat Asif1, Fatima Malik2, Abdul Salar Khan3

  • 1Medicine, Khawaja Muhammad Safdar Medical College, Sialkot, PAK.

Cureus
|January 17, 2025
PubMed
Summary

Acetazolamide enhances decongestion and reduces neurohormonal activation in acute heart failure (HF). This carbonic anhydrase inhibitor improves outcomes by increasing urinary chloride excretion and lowering renin and aldosterone levels.

Keywords:
acetazolamidechloride excretionheart failureneurohormonal modulationrenin-angiotensin-aldosterone system (raas)

More Related Videos

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
08:31

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction

Published on: July 26, 2018

10.1K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.3K

Related Experiment Videos

Last Updated: Jun 1, 2025

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

9.9K
Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
08:31

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction

Published on: July 26, 2018

10.1K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.3K

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Heart failure (HF) management traditionally focuses on sodium (Na) and water balance, with arterial circulation influencing renal excretion.
  • Chloride (Cl) is increasingly recognized for its role in HF, impacting volume regulation and renin-angiotensin-aldosterone system (RAAS) activity via macula densa signaling.
  • Acetazolamide, a carbonic anhydrase inhibitor, may improve decongestion in HF by increasing urinary Na and Cl excretion alongside loop diuretics.

Purpose of the Study:

  • To investigate the neurohormonal effects of acetazolamide in patients with acute heart failure (HF).
  • To assess acetazolamide's ability to enhance decongestion and reduce neurohormonal activation, including renin and aldosterone levels.
  • To evaluate the modulation of RAAS markers by acetazolamide in acute HF.

Main Methods:

  • Prospective, single-center observational study involving 80 acute HF patients.
  • Two groups: case group (n=40) received acetazolamide with standard therapy; control group (n=40) received standard therapy alone.
  • Comparison of baseline characteristics, plasma renin activity (PRA), aldosterone, electrolytes, and clinical outcomes between groups.

Main Results:

  • The acetazolamide group showed significantly higher urinary Cl excretion (p<0.001).
  • Reduced PRA and aldosterone levels were observed in the acetazolamide group compared to controls (p=0.002 and p=0.006, respectively).
  • Improved clinical outcomes included more patients symptom-free within 72 hours (77.5% vs. 52.5%; p=0.018) and shorter hospitalization (5.6 vs. 7.1 days; p=0.028).

Conclusions:

  • Acetazolamide, as an adjunct to standard therapy, enhances decongestion and reduces neurohormonal activation in acute HF.
  • The findings suggest a dual benefit of acetazolamide in fluid management and RAAS modulation for acute HF.
  • Further research is warranted to confirm long-term benefits and address study limitations, such as the single-center observational design.